Bluebird Bio hits pause on rollout for ill-fated gene therapy Zynteglo as trial flags 2 cancer cases | Fierce Pharma
Bristol-Myers' Acquisition of - GuruFocus.com
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
Bluebird Spinoff 2seventy Bio Gets Its Own Wings :: Scrip
MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin
BLUEBIRDBIO
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert – GeekWire
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership | Fierce Pharma
Bluebird bio snares gene-editing tech in $156M buyout deal | Fierce Biotech
BLUEBIRDBIO
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A (NASDAQ:BLUE) | Seeking Alpha
Bluebird Bio $BLUE : r/HellsTradingFloor
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 | Fierce Biotech
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first | Fierce Pharma
BLUEBIRDBIO
Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
The top 10 takeover targets in biopharma | Fierce Biotech
